This site is intended for Great Britain healthcare professionals only 

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Menu

Close

AboutAboutHow Cibinqo worksIntroducing CibinqoMOA OverviewPatient ProfilesPatient Profiles OverviewPatient Profile 1Patient Profile 2Patient Profile 3Patient Profile 4EfficacyEfficacyClinical EfficacyStudy OverviewJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDSafety
Safety
 
Safety
 
Safety Guidance
DosingDosingDosingOral once-daily dosingPractical ConsiderationsSupport & ResourcesSupport & ResourcesHCP ResourcesMedicine Evidence InformationPatient ResourcesVideos
Materials

Information on how to access Cibinqo® (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

JADE MONOCibinqo efficacy as monotherapy, without medicated topical therapy1–3​​​​​​​

Two identically designed Phase III studies (MONO-1 and MONO-2) evaluated the efficacy and safety of Cibinqo as monotherapy in 387 and 391 patients with moderate-to-severe AD. Patients were assessed without medicated topical therapy and rescue treatment was not permitted during the trials.1–3

STUDY DESIGN1-3

*Patients not eligible for JADE EXTEND entered the 4-week off-treatment follow-up period.

Co-primary endpoints:
  • EASI-75 response at Week 12 vs placebo
  • ​​​​​​​IGA 0/1 response with ≥2-point improvement at Week 12 vs placebo
Key secondary endpoints:
    • PP-NRS4 response at Weeks 2, 4 and 12 (defined as an improvement of ≥4 points from baseline in the severity of PP-NRS)
    • PSAAD response at Week 12
    Baseline characteristics: MONO-12
    Scroll left to view table

    Placebo (N=77) ​​​​​​ Cibinqo 100 mg (N=156) ​​​​​​Cibinqo 200 mg (N=154)
    Age, years ​​​​​​​ 31.5 (14.4) 32.6 (15.4) 33.0 (17.4)
    Age group, years (%)
    • <18
    • 18–65
    • ≥65
     
    ​​​​​​​• 17 (22)
     59 (77)
    ​​​​​​​• 1 (1)
     
     
    ​​​​​​​• 34 (22)
     118 (76)
    ​​​​​​​• 4 (3)
     
     
    ​​​​​​​• 33 (21)
     110 (71)
    ​​​​​​​• 11 (7)
     
    Sex, female, n (%)  
    ​​​​​​​28 (36)
     
    66 (42)

    73 (47)
    Race, n (%)
    • White
    • Black
     Asian
     Other*
    ​​​​​​​• Not reported

     
    ​​​​​​​• 62 (81)
    • 6 (8)
    • 6 (8)
    • 2 (3)
    ​​​​​​​• 1 (1)
     
     
    ​​​​​​​• 113 (72)
    • 15 (10)
    • 26 (17)
    • 2 (1)
    ​​​​​​​• 0
     
     
     104 (68)
    • 11 (7)
    • 26 (17)
    • 11 (7)
    ​​​​​​​• 2 (1)
     
    AD duration, years (SD)  
    ​​​​​​​22.5 (14.4)
     
    24.9 (16.1)
     
    22.7 (14.5)
    Previous medication for AD
    • Any previous medication
    • Topical drugs alonealone
    • Systemic medication ± topical therapy§
     ​​​​​​​Dupilumab
     
    ​​​​​​​• 77 (100)
    • 34 (44)
    • 41 (53)
    • 8 (10)
     
     
    ​​​​​​​• 155 (99)
    • 69 (44)
    • 78 (50)
    ​​​​​​​• 13 (8)
     
     
    ​​​​​​​• 154 (100)
    • 82 (53)
    • 68 (44)
    ​​​​​​​• 9 (6)
     
    IGA score
    • 3 (moderate disease)
    • 4 (severe disease)

     
    ​​​​​​​• 46 (60)
    ​​​​​​​• 31 (40)
     
     
    ​​​​​​​• 92 (59)
    ​​​​​​​• 64 (41)
     
     
    ​​​​​​​• 91 (59)
    ​​​​​​​• 63 (41)
     
    EASI score 28.7 (12.5)
    31.3 (13.6)
    30.6 (14.1)
    BSA affected, % (SD) 47.4 (22.7)
    50.8 (23.4)
    49.9 (24.4)
    SCORAD score 64.5 (13.2)
    67.1 (13.7)
    64.3 (13.1)
    PP-NRS score 7.0 (1.8)
    6.9 (2.0)
    7.1 (1.9)
    ​​​​​​​PSAAD total score#​​​​​​​  
    ​​​​​​​5.5 (2.0)


    5.3 (2.3)
    ​​
     
    5.4 (2.1)
    ​​​​​​
    DLQI total score** 13.9 (7.3)
    14.6 (6.5)
    14.6 (6.8)
    CDLQI total score†† 13.6 (7.0)
    11.7 (6.6)
    13.2 (5.5)
    POEM total score‡‡ 19.9 (6.1)
    19.5 (6.5)
    19.6 (5.9)

    *Includes patients that were American Indian or Alaskan Native, Native Hawaiian or Pacific Islander, or multiracial.
    Patients were counted for each main category in an exclusive manner.
    Topical agents includes corticosteroids and calcineurin inhibitors.
    §Systemic agents includes mycophenolate mofetil, methotrexate, azathioprine, corticosteroids, ciclosporin and dupilumab.
    Data were available for 77 patients in the placebo group, 155 patients in the Cibinqo 100 mg group, and 154 patients in the Cibinqo 200 mg group.
    #Data were available for 68 patients in the placebo group, 137 patients in the Cibinqo 100 mg group, and 138 patients in the Cibinqo 200 mg group.
    ​​​​​​​**Assessed in patients aged 18 years; data were available for 60 patients in the placebo group, 121 patients in the Cibinqo 100 mg group, and 119 patients in the Cibinqo 200 mg group.
    ††Assessed in patients aged <18 years; data were available for 16 patients in the placebo group, 32 patients in the Cibinqo 100 mg group, and 32 patients in the Cibinqo 200 mg group.
    ‡‡Data were available for 77 patients in the placebo group, 153 patients in the Cibinqo 100 mg group, and 153 patients in the Cibinqo 200 mg group.

    Baseline characteristics: MONO-23
    Scroll left to view table

    Placebo (N=78) ​​​​​​​​​​​ Cibinqo 100 mg (N=158)
    Cibinqo 200 mg (N=155)
    Age, years (SD) ​​​​​​​​​​​​​ 33.4 (13.8)
    37.4 (15.8)
    33.5 (14.7)
    Age group, years (%)
    • <18
    • 18–65
    • ≥65
     
    ​​​​​
    ​​​​​​​• 8 (10.3)
    • 69 (88.5)
    ​​​​​​​• 1 (1.3)

     
     
    ​​​​​​​ 
    ​​​​​​​• 17 (10.8)
    • 130 (82.3)
    ​​​​​​​• 11 (7.0)
     
     
     
     
    ​​​​​​​• 15 (9.7)
    • 133 (85.8)
    ​​​​​​​• 7 (4.5)
     
     
    Male
     
    ​​​​​​​47 (60.3)
     
    94 (59.5)

    88 (56.8)
    Race, n (%)
    • White
    • Asian
     Black
     Multiracial
    ​​​​​​​• Not reported

     
    ​​​​​​​ 
    ​​​​​​​• 40 (51.3)
    • 29 (37.2)
    ​​​​​​​• 6 (7.7)
    • 1 (1.3)
    ​​​​​​​• 2 (2.6)
     
     
     
    ​​​​​​​• 101 (63.9)
    • 46 (29.1)
    • 9 (5.7)
    • 1 (0.6)
    ​​​​​​​• 1 (0.6)
     
     
     91 (58.7)
    • 54 (34.8)
    • 6 (3.9)
    • 2 (1.3)
    ​​​​​​​• 2 (1.3)
     
    Disease duration, years (SD)
     
    ​​​​​​​21.7 (14.3)
     
    21.1 (14.8)
     
    20.5 (14.8)
    Prior prescribed or OTC medication for AD*
    • Any
    • Anti-inflammatory topical agents
    • Systemic agents
     ​​​​​​​Dupilumab
     
     
    ​​​​​​​​​​​​​​
    ​​​​​​​• 78 (100)
    • 46 (59.0)
    • 32 (41.0)
    ​​​​​​​• 2 (2.6)
     
     
     
    ​​​​​​​
    ​​​​​​​•157 (99.4)
    • 87 (55.1)
    • 70 (44.3)
    ​​​​​​​• 7 (4.4)
     
     
     
    ​​​​​​​
    ​​​​​​​• 153 (98.7)
    • 93 (60.0)
    • 60 (38.7)
    ​​​​​​​• 5 (3.2)
     
     
    IGA score
    • 3 (moderate disease)
    • 4 (severe disease)

     
     
    ​​​​​​​• 52 (66.7)
    ​​​​​​​• 26 (33.3)
     
     
    •107 (67.7)
    ​​​​​​​• 51 (32.3)
     
     
     
    ​​​​​​​• 106 (68.4)
    ​​​​​​​• 49 (31.6)
     
     
    EASI score, mean (SD)
    28.0 (10.2)
    28.4 (11.2)
    29.0 (12.4)
    BSA affected, % (SD) 48.2 (20.8)
    48.7 (21.4)
    47.7 (22.3)
    SCORAD score, mean (SD)
    64.3 (12.4)
    63.8 (11.4)
    64.1 (13.1)
    PP-NRS score, mean (SD)
    6.7 (1.9)
    7.1 (1.6)
    7.0 (1.6)
    ​​​​​​​PSAAD score, mean (SD)​​​​​​  
    5.1 (2.1)


    5.4 (2.1)
    ​​
     
    5.2 (2.0)
    ​​​​​​
    DLQI score, mean (SD)
    15.0 (7.1)
    15.4 (7.3)
    14.8 (6.0)
    POEM score, mean (SD)
    19.2 (5.5)
    20.9 (5.7)
    19.7 (5.7)

    *Patients were counted once for each main category in an exclusive manner, with systemic agents, biologics and/or topical agents taking precedence over anti-inflammatory topical agents alone.

    Inclusion/exclusion criteria2,3INCLUSION CRITERIA2,3
    • ≥12 years of age
    • Body weight ≥40 kg
    • Clinically diagnosed with chronic AD for ≥1 year, confirmed by Hanifin and Rajka criteria of AD at the screening and baseline visits. Criteria for AD diagnosis include ≥3 of the basic features of pruritus: typical morphology and distribution, including flexural lichenification or linearity in adults and facial and extensor involvement in infants and children; chronic or chronically relapsing dermatitis; and personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis); along with ≥3 of 23 minor features specified in the criteria
    • Have a documented history of inadequate response to treatment with topical medications, is not medically advisable, or require systemic therapies to control their disease
    • Moderate-to-severe AD defined as BSA ≥10%, IGA ≥3, EASI ≥16 and PP-NRS ≥4 at the baseline visit
    EXCLUSION CRITERIA2,3
    • Active forms of other inflammatory skin diseases
    • Prior treatment with any systemic JAK inhibitors
    • Vaccination with, or exposure to, a live or attenuated vaccine within 6 weeks prior to the first dose
    • Participation in other clinical studies involving investigational drug(s) within 8 weeks prior to study entry
    • Uncontrolled, clinically significant laboratory abnormality that could affect study interpretation
    • Any major psychiatric condition
    • Unwillingness to discontinue current AD medications prior to the study
    • Requiring treatment with prohibited medications during the study
    • Medical history of thrombocytopenia, coagulopathy or platelet dysfunction, or Q wave interval abnormalities
    • Presence or history of certain infections, cancers, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
    • Pregnant or breastfeeding women
    • Women of childbearing potential who are unwilling to use contraception
    PRIMARY ENDPOINT – SKIN CLEARANCEWith Cibinqo, significantly more patients achieved skin clearance vs placebo1–3

    In 12 weeks, ~60% of patients achieved EASI-75 with Cibinqo 200 mg monotherapy in both MONO 1 and MONO 2 trials vs ~11% for placebo.2,3

    Proportion of patients achieving EASI-75, MONO-11,2​​​​​​​
    Scroll left to view table
    EASI-75 at Week 12 no./Total no. (%, 95% CI)
    Cibinqo 200 mg 96/153 (62.7%; 55.1–70.4)
    Cibinqo 100 mg 62/156 (39.7%; 32.1–47.4)
    Placebo 9/76 (11.8%; 4.6–19.1)
    Proportion of patients achieving EASI-75, MONO-21,3,4

    In 12 weeks, ~40% of patients achieved IGA 0/1 with Cibinqo 200 mg monotherapy in both MONO-1 and MONO-2 trials vs ~9% for placebo.2,3

    Scroll left to view table
    Scroll left to view table
    He Header
    Content Content
    Content Content
    Content Content
    Content Content
    Content Content
    EASI-75 at Week 12 no./Total no. (%, 95% CI)
    Cibinqo 200 mg 94/154 (61.0%; 53.3–68.7)
    Cibinqo 100 mg 69/155 (44.5%; 36.7–52.3)
    Placebo 8/77 (10.4%; 3.6–17.2)
    Proportion of patients achieving IGA 0/1, MONO-11,2​​​​​​​
    Scroll left to view table
    IGA 0/1 at Week 12 no./Total no. (%, 95% CI)
    Cibinqo 200 mg
    67/153 (43.8%; 35.9–51.7)
    Cibinqo 100 mg
    37/156 (23.7%; 17.0–30.4)
    Placebo 6/76 (7.9%; 1.8–14.0)
    Proportion of patients achieving IGA 0/1, MONO-21,3,4​​​​​​​
    Scroll left to view table
    IGA 0/1 at Week 12 no./Total no. (%; 95% CI)
    Cibinqo 200 mg 59/155 (38.1%; 30.4–45.7)
    Cibinqo 100 mg 44/155 (28.4%; 21.3–35.5)
    Placebo 7/77 (9.1%; 2.7–15.5)
    KEY SECONDARY ENDPOINT – ITCH REDUCTIONCibinqo achieved rapid and significant itch relief vs placebo1–3​​​​​​​

    As early as Week 2, both doses of Cibinqo achieved differentiation from placebo in itch relief, as measured by PP-NRS4.1–3

    Proportion of patients achieving PP-NRS4, MONO-11,2​​​​​​​​​​​​​​Proportion of patients achieving PP-NRS4, MONO-21,3,4
    Explore moreSafety

    3,128 patients were treated with Cibinqo in clinical studies in AD representing 2,089 patient-years of exposure.1

    View safety guidanceLoading
    • References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics.

    Dosing

    Learn more about flexible dosing in patients on Cibinqo.

    Discover oral once-daily dosingLoading

    AD=atopic dermatitis; BSA=body surface area; CDLQI=Children's Dermatology Life Quality Index; CI=confidence interval; DLQI​​​​​​​=Dermatology Life Quality Index; EASI=Eczema Area and Severity Index; IGA=Investigator’s Global Assessment; JAK=Janus kinase; OT=over-the-counter; POEM=Patient-Oriented Eczema Measure; PP-NRS=Peak Pruritus Numerical Rating Scale; PSAAD=Pruritus and Symptoms Assessment for Atopic Dermatitis; SCORAD=SCORing Atopic Dermatitis; SD=standard deviation.

    Prescribing information:
    Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
    Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
    Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.

    References:

    Cibinqo (abrocitinib) Summary of Product Characteristics.Simpson E, et al. Lancet 2020;396:P255–266.Silverberg J, et al. JAMA Dermatol 2021;156(8):863–873.Silverberg J, et al. JAMA Dermatol 2021;156(8):863–873. Supplementary appendix.
    PP-CIB-GBR-0063. October 2021

    Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

    for MHRA Yellow Card in Google Play or Apple App Store


    Adverse events should also be reported to Pfizer Medical Information on 01304 616161

    PfizerPro Account

    To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

    Sign In or RegisterAccountSign Out

    This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


    This website is brought to you by Pfizer Limited, a company registered in England 

    and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


    Copyright © 2021 Pfizer Limited. All rights reserved.


    VAT registration number GB201048427

    PP-PFE-GBR-3849. November 2021

    Add indication message here. It can link a link,
    and you can EMBOLDEN text

    OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

    If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

    Would you like to register or sign in now?

    You are now leaving PfizerPro
    ​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

    ​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

    ​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
    ​​​​​​​
    For UK Healthcare Professionals *

    These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

    I confirm that I am a healthcare professional* resident in the United Kingdom.

    If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

    *The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

    PP-PFE-GBR-3863. November 2021

    Yes No
    You are now leaving PfizerPro
    ​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

    Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
    business which it has provided or reviewed.

    PP-PFE-GBR-3859. November 2021
    ​​​​​​​